** Shares of rare neurological disease-focused pharma company Harmony Biosciences HRMY.O up 3.7% at $35.44 premarket
** Company posts Q4 adj profit of $1.08 per share, beating analysts' estimates of 74 cents per share, according to data compiled by LSEG
** Co records Q4 sales of sleep disorder drug, Wakix, at $201.3 million, beating analysts' estimates of $200 million
** Expects 2025 net product revenue of $820 million to $860 million, midpoint of which is below analysts' estimates of $848 million
** In the last 12 months, HRMY rose 4.7%
(Reporting by Siddhi Mahatole)
((Siddhiprabhanjan.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.